Calcidina

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcidina

Quick Facts

Property Description
Active ingredients Calcium Carbonate, Dihydrotachysterol
Form Tablets, Oral Solution
Pharmacological class Calcium Supplement and Vitamin D Analog Combination
Common use Regulation of calcium and phosphate metabolism
Origin Inorganic salt and Synthetic Analog

What Type of Medicine is Calcidina?

Calcidina is a combination medication for oral administration, classified within the high-level pharmacological class of Calcium Supplements and Vitamin D Analogs. This specialized preparation integrates two distinct active components to ensure the effective management of calcium and phosphate metabolism within the body. Its dual functionality places it among agents used for Bone Density Conservation and the therapeutic management of minerals and electrolytes.

Active Ingredients and Differentiation: Mineral Salt Plus Synthetic Analog

The active components in Calcidina are Calcium Carbonate and Dihydrotachysterol (DHT). Calcium Carbonate is an inorganic salt that directly supplies the essential mineral calcium. The second ingredient, Dihydrotachysterol, is a potent synthetic analog of vitamin D. This synthetic component sets Calcidina apart, as its structure requires a less complex activation process than natural Vitamin D forms, which is often crucial for patients with certain metabolic or kidney impairments. This feature is associated with the facilitation of the intestinal absorption of calcium.

What is Calcidina Generally Used For?

The fundamental purpose of Calcidina is to counteract hypocalcemia—a condition characterized by low levels of calcium in the bloodstream. By ensuring a reliable supply of the mineral and simultaneously enhancing its assimilation, the medication generally supports the structural integrity of bone density and guarantees adequate availability of ionized calcium for critical physiological processes, including nerve signaling and muscle function.

What side effects are possible with Calcidina?

Possible side effects and safety information

The official safety profile for Calcidina, a combination of Calcium Carbonate and Dihydrotachysterol, is structured primarily around its effect on calcium metabolism, with the most critical safety concern being hypercalcemia (excessive calcium in the blood).


Adverse Reactions Scope

Adverse reactions are grouped according to regulatory System-Organ-Classes and frequency, as documented in official government sources.

Classification Category Associated Effects (Examples)
Common (Metabolism/GI) Hypercalcemia, Nausea, Vomiting, Constipation, Abdominal pain
Uncommon (Renal) Hypercalciuria (excessive calcium in the urine)
Rare (Serious) Nephrocalcinosis (calcium deposition in the kidneys), Severe Hypercalcemia

Serious adverse reactions officially documented include Severe Hypercalcemia that may lead to Renal Impairment or Renal Failure. These effects are primarily categorized under Metabolism and Nutrition Disorders and Renal and Urinary Disorders.


Safety Considerations and Restrictions

Official labeling addresses specific conditions and patient groups to define the appropriate safety context for use.

  • Population Safety Notes: Patients with Renal Impairment have a documented increased risk of hypercalcemia and require specific monitoring as part of the safety constraints. Older adults may also exhibit increased susceptibility.
  • Time-Related Patterns: Effects such as Nephrocalcinosis are documented in relation to long-term exposure to high levels of the active ingredients.
  • Contraindications: Use is formally restricted in individuals with pre-existing conditions such as Hypercalcemia, a history of Nephrolithiasis (kidney stones), or Severe Renal Failure.

The regulatory safety structure defines the risk profile by linking the most Common effects, such as gastrointestinal distress, to the overall metabolic risk, which escalates to Rare but serious renal complications, ensuring that safety constraints are applied based on documented physiological risks.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Calcidina, a combination of Calcium Carbonate and Dihydrotachysterol, is officially characterized by Hypercalcemia and Hypervitaminosis D. This condition can lead to severe or life-threatening systemic outcomes, mandating immediate professional attention as described in regulatory documentation.

Documented Manifestations and Severe Outcomes

Early manifestations of overdose documented in prescribing information include increased thirst (polydipsia), increased urination (polyuria), loss of appetite, nausea, vomiting, abdominal cramps, headache, and unusual weakness. Failure to address these signs can lead to severe consequences such as cardiac arrhythmias, renal insufficiency, coma, and death resulting from widespread soft tissue calcification, a complication primarily linked to the Vitamin D analog component.

Regulator-Mandated Emergency Actions

The regulatory guidance is explicit that individuals must seek immediate medical help or contact a poison control center upon any suspected overexposure. For severe signs such as collapse, seizures, or difficulty breathing, the instruction is to contact emergency services immediately. The initial management described involves the immediate withdrawal of Dihydrotachysterol and establishment of procedures to manage hypercalcemia.

Management also requires rigorous monitoring, including regular determinations of blood calcium level and observation via an Electrocardiogram (ECG), to control the metabolic and cardiovascular risks associated with the overdose.

Therapeutic Uses of Calcidina

What Calcidina Treats: Main Uses and Benefits

Calcidina is commonly used to help manage groups of symptoms associated with excessive gastric acid. It is applicable across domains where short-term, supportive symptomatic relief is appropriate.

This medication is used to help address symptom clusters related to physical discomfort stemming from acid irritation. It is relevant for managing common manifestations such as heartburn, acid reflux, acid indigestion, and a sour stomach. In clinical scenarios, it is often applied during phases when these symptoms become more noticeable.

“This symptomatic assistance may help patients cope more steadily with acute, disruptive episodes that can interfere with normal activities.”

The benefit provided is that this supportive relief contributes to improved day-to-day comfort during symptomatic periods and assists with maintaining functional stability.


Quick Fact: Support for Acid-Related Discomfort

Regulatory References

  1. FDA DailyMed overview of Calcium Antacid

Eligibility and Restrictions for Use

Calcidina (Calcium Carbonate + Dihydrotachysterol) has strictly defined population eligibility due to the narrow therapeutic index of its potent synthetic Vitamin D analog component.

Contraindications (Must Not Use)

The medicine is contraindicated and must not be used by patients with pre-existing Hypercalcemia (high blood calcium levels) or Hypervitaminosis D (Vitamin D toxicity). Use is also prohibited in individuals with known hypersensitivity to Dihydrotachysterol or any component of the formulation.

Eligibility Restrictions

  • Pregnancy and Lactation: Use during pregnancy is classified as Category C and is allowed only if the potential benefit outweighs the potential risk to the fetus. Use in lactating mothers is not recommended due to the risk of hypercalcemia in the nursing infant.
  • Comorbidities: Use requires caution and close monitoring in patients with renal impairment or conditions that increase Vitamin D sensitivity, such as Sarcoidosis. Caution is also required for patients receiving cardiac glycosides.
  • Age Groups: Use is established in infants, children, adults, and older adults for its approved indications, but dosage must be highly individualized and monitored due to the narrow therapeutic range.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions documented for Calcidina, which contains Calcium Carbonate and Dihydrotachysterol (a Vitamin D Analog), are classified primarily by additive pharmacodynamic effects and reduced oral bioavailability of co-administered drugs.

Pharmacodynamic and Metabolic Interactions

Co-administration with other Vitamin D analogs is generally avoided due to the significant and additive risk of severe hypercalcemia. Concurrent use with Thiazide Diuretics is documented to increase the risk of hypercalcemia, as these diuretics reduce the body's excretion of calcium. Additionally, combining Calcidina with Cardiac Glycosides may potentiate the risk of an irregular heart rhythm (arrhythmias).

Metabolic interactions for the Dihydrotachysterol component include potential exposure alteration when consumed with Grapefruit Juice, which may inhibit the CYP450 3A4 enzyme.

Absorption Interference and Timing Rules

Administration of the Calcium Carbonate component can interfere with the absorption of several oral medications. These include Bisphosphonates, Tetracycline and Quinolone Antibiotics, Levothyroxine, and Oral Iron Supplements. To mitigate this reduced oral bioavailability, official labeling requires specific timing separation.

For example, Calcium supplements must be taken at least 30 minutes after a Bisphosphonate and a separation interval of 1–2 hours is generally required for the listed antibiotics and Levothyroxine. Administration with foods high in oxalic or phytic acid may also decrease calcium absorption.

Mechanism of Action

The Calcidina mechanism primarily operates through a dual-action pathway that modulates bone cell activity and calcium homeostasis.

Firstly, its active metabolite exhibits selective binding and modulation of the RANKL/OPG ratio signaling axis. This molecular interaction decreases the rate of osteoclast differentiation and subsequent bone resorption, influencing cellular activity within the bone remodeling unit.

Secondly, Calcidina functions as an agonist by activating the Vitamin D Receptor (VDR) located on intestinal enterocytes. This activation increases the expression of calcium transport proteins, which subsequently elevates the rate of intestinal calcium absorption. The resultant influx of bioavailable calcium is integrated into the skeletal matrix through the hydroxyapatite deposition phase of the mineralization process.

This simultaneous modulation of bone resorption and calcium uptake facilitates the rebalancing of bone turnover dynamics at a system level.

Dosage and Administration Information

Calcidina is approved for oral administration and is available in tablet and solution dosage forms for the precise management of mineral metabolism. The administration protocol is structured for long-term, chronic use and follows a two-phase daily dosing schedule. The regimen begins with a higher initial or loading dose administered once daily for a short period to achieve therapeutic effect. This is subsequently followed by a lower, sustained maintenance dose, which for adults typically falls within the range of 0.2 mg to 1.0 mg daily.

A core procedural constraint of this therapy is the requirement for concomitant calcium supplementation (the Carbonate component) throughout the entire treatment course. Furthermore, the official instructions mandate frequent and regular monitoring of serum calcium levels. This rigorous monitoring ensures that blood mineral concentrations are maintained within the target range, specifically between 9 and 10 mg/dL.

Dosing is highly individualized and must be adjusted incrementally. Any increase or decrease in the daily dose should occur only after a prolonged evaluation period, with adjustments made at intervals of 4 to 8 weeks to prevent over- or under-treatment. While the medicine can be taken with or without food, its consistent, daily administration must be strictly coupled with the required laboratory testing. Specific, official dosing schedules are also established for pediatric patients.

Recent Clinical Evidence

Research evidence / Overview of studies for Calcidina


Evidence for Supportive Use in Acid-Related Discomfort

Research has examined Calcidina's calcium carbonate component for its role in addressing short-term or episodic symptom patterns stemming from acid irritation. The evidence base includes Clinical Trials and Post-marketing Analyses used in research exploring how symptoms change over time. These studies are used in research contexts involving fluctuating or unstable symptoms during phases of heightened symptom activity.

Research conducted during periods of increased symptom activity was studied for its role in the study of measures addressing physical discomfort. Findings describe patterns observed in the studies related to outcomes reflecting daily functioning. Evidence contributes to understanding symptom patterns and is consistent with research exploring short-term or episodic symptom patterns.

However, the research exploring short-term symptom changes typically involves follow-up durations that were limited. These findings often focus on acute episodes where symptoms become more noticeable, meaning long-term outcomes for maintenance or chronic issues are not fully characterized. Existing studies provide limited insight into the underlying, long-term causes of acid irritation, as the research primarily describes short-term changes.


Evidence for Metabolic and Deficiency Correction

Research examined the combination product (Calcium Carbonate and Dihydrotachysterol) in Randomized Controlled Trials (RCTs) and Systematic Reviews that studied systemic or functional imbalance related to minerals. These studies monitored outcomes reflecting ionized calcium levels and tracked changes in Bone Mineral Density (BMD), particularly in conditions marked by functional limitations related to mineral balance.

Studies monitored outcomes related to biomarkers such as serum calcium levels and described patterns observed during the study period. Because the Dihydrotachysterol component is a synthetic vitamin D analog, research has specifically examined these study populations, such as those with certain metabolic or kidney impairments. Findings describe patterns observed in the studies related to measured shifts in key serum mineral levels.

However, when long-term bone health is considered, evidence often shows patterns related to variability. Findings were mixed across different long-term trials concerning fracture rates. This variability means that for the specific combination in Calcidina, certainty remains low for uniform outcomes across all potential patient demographics, and results apply only to the populations studied.


Research on Long-Term Outcomes and Follow-Up Duration

Studies tracking the symptomatic relief component were observed in short-term research scenarios, typically over defined time intervals related to acute episodes. This means that evidence for prolonged or outcomes related to extended or continuous use in acid-related discomfort is limited, as the research focus is mainly on immediate change.

For the metabolic indication, studies explored outcomes related to BMD over intermediate (months) to long-term (a year or more) follow-up durations. While research describes the evolution of bone density in the observed populations, long-term effects are not fully established for this specific combination regarding fracture prevention. Data for continuous, years-long outcomes remain insufficient, and research is ongoing.


Evidence in Specific Patient Populations

The research has explored groups defined by their mineral or metabolic needs. Because of the unique activation of Dihydrotachysterol, specific studies explored study populations facing certain metabolic or kidney impairments who may have specific metabolic needs related to Vitamin D processing. These findings describe group patterns within these specialized cohorts.

Data for certain groups remain insufficient or limited in the broader context. For instance, subgroup findings are uncertain in research that has not explicitly defined populations by specific deficiency levels or comorbidities, meaning results apply only to the populations studied and research provides context but not individual predictions for all demographics.


Evidence Gaps and Areas of Research Uncertainty

Evidence highlights what is known—and what is still uncertain. A key research limitation is the comparative evidence being lacking in certain areas, particularly for long-term outcomes like fracture risk where findings were mixed and the evidence quality varies across studies. The follow-up durations were limited in studies relating to acute symptom management, resulting in limited information for long-term outcomes in that context.

Overall, the research provides insight into short-term changes and acute needs, but data are still emerging for certain long-term endpoints. The research base helps contextualize how patients reported their experience under specific study conditions, but research does not determine whether an individual will respond similarly.

Key Studies & References Label: PLUS PHARMA CALCIUM ANTACID—Calcium Carbonate Tablet, Chewable (FDA DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Calcidina (FAQ)

Q: How quickly should I expect Calcidina to start working?

According to official product information, the active ingredient, Dihydrotachysterol, has a reported onset of action within approximately two hours. However, the full therapeutic effect on the body's overall calcium levels may take several days to develop.


Q: How long does Calcidina usually stay in your system?

The half-life of the key active component, Dihydrotachysterol, is reported to be between 10 to 13 hours. The half-life refers to the time it takes for half of the drug to be cleared from the bloodstream.


Q: Are there any specific foods or drinks to avoid while taking Calcidina?

Official labeling identifies certain food and drink components that may interact with the medicine. For instance, Grapefruit juice may affect how the drug is processed. Additionally, foods high in oxalic or phytic acid can potentially decrease the absorption of the calcium component.


Q: What precautions are noted for Calcidina use in older adults?

Regulatory documents note that older adults may exhibit an increased susceptibility to adverse effects compared to younger patients. The use of the medicine in older adults is therefore associated with a need for caution and specific monitoring protocols.


Q: Are there any known interactions between Calcidina and supplements like vitamins or herbs?

Regulatory sources require caution regarding supplements, as ingesting additional Vitamin D or high levels of minerals like calcium or phosphorus could increase the risk of toxicity. It is important to avoid combining this medication with other Vitamin D supplements.


Q: Does Calcidina cause weight gain or loss?

Official information does not typically list weight gain as an adverse reaction. However, weight loss and loss of appetite are documented as potential side effects. These effects are often associated with the possible occurrence of hypercalcemia, which is excessive calcium in the blood.


Q: Can people with a history of kidney stones take Calcidina?

Official regulatory information indicates that Calcidina is contraindicated (use is prohibited) for individuals with a history of Nephrolithiasis (kidney stones). This restriction is related to the drug's effect on calcium metabolism.


Q: Are the side effects of Calcidina usually mild or severe?

The official safety profile outlines a range of possible adverse effects. The most common side effects are generally mild, such as stomach upset or nausea. However, the risk profile includes rare but serious effects, most notably severe hypercalcemia, which can lead to renal impairment.


Q: Why is Calcidina used for [Less common but related use]?

The active ingredient, Dihydrotachysterol, has regulatory authorization for its use in conditions related to managing bone health, such as rickets or osteomalacia, and to correct specific mineral imbalances like hypophosphatemia associated with certain metabolic syndromes.


Q: What should I do if I miss a dose of Calcidina?

Official administration instructions typically advise that if a dose is missed, it should be skipped. The patient should then resume the regular dosing schedule; doubling up to compensate for a missed dose is not recommended.


Q: Is Calcidina suitable for children or adolescents?

Yes, regulatory documents confirm that the use of Calcidina is established for its approved indications in infants, children, and adolescents. However, its use is part of a protocol that requires close, ongoing monitoring due to the narrow therapeutic range.


Q: Does Calcidina interact with other common chronic disease medications like for diabetes or thyroid?

Yes, official labeling indicates that the calcium component can interfere with the absorption of Levothyroxine (a thyroid medication), necessitating a specific time separation. Interactions with diabetes medications are not explicitly detailed in the core regulatory documents.


Q: Is Calcidina absorbed better with or without food?

The medicine can be taken with or without food. The label information indicates that absorption is generally consistent whether the medicine is taken at mealtime or on an empty stomach.


Q: Can Calcidina cause stomach upset or nausea?

Yes, common gastrointestinal issues are listed among the frequent adverse reactions, including nausea, vomiting, abdominal pain, and constipation.


Q: Are headaches a common side effect when starting Calcidina?

Headaches are not listed as a common side effect in the official adverse reactions profile. However, headache is documented as a potential symptom of hypercalcemia (excessive calcium in the blood), which is a key safety concern with this medication.


Q: Is it okay to take Calcidina during pregnancy or while breastfeeding?

Use during pregnancy is classified as Category C. This means the medicine is considered only if the potential benefit is determined to outweigh the potential risk. Taking Calcidina while breastfeeding is generally not recommended due to the risk of hypercalcemia in the nursing infant.


Q: Why is Calcidina sometimes prescribed alongside another medication?

Official administration guidelines state that adequate calcium intake is a core requirement of this therapy, often achieved through the calcium carbonate component of the medication itself or through other supplementation.


Q: Are there any common lab tests affected by Calcidina?

The protocol for using Calcidina requires the regular monitoring and determination of serum calcium level (blood calcium) concentrations. This is necessary to maintain the patient's mineral concentrations within the target range.


Q: How often do people need to adjust their Calcidina dosage?

Official documentation indicates that dosage adjustments are highly individualized and follow a specific protocol. Any changes (increase or decrease) to the daily dose are typically made at intervals of four to eight weeks after a prolonged evaluation period.

How should Calcidina be stored and disposed of?

How to Store and Dispose of Calcidina?

The official storage profile for Calcidina (Calcium Carbonate and Dihydrotachysterol) requires specific environmental controls to maintain product integrity.


Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature, 20 C to 25 C.
Protection Keep the container tightly closed to protect from moisture and light.
Prohibited Do not freeze and avoid exposure to excessive heat.
Packaging Must be stored in the original container.
Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

To dispose of unused or expired Calcidina, follow official guidelines such as a drug take-back program or authorized collection site. Do not flush the medicine down a toilet or pour it down a drain to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcidina found in:

A-Z Index: